Group 1 - Shaanxi Biochemical Industry Technology Innovation Platform Co., Ltd. (referred to as "Shaanxi Biochemical") and its parent company Huason Shengbang are making significant advancements in the fields of biopharmaceutical intermediates, raw materials, and health food ingredients [1] - In 2021, a core team of five, led by Chairman Weng Jing and General Manager Li Pumin, initiated a "second entrepreneurship" to tackle "bottleneck" technologies, establishing a complete chain from basic research to industrialization [1] - The projects on resveratrol and rhodiola glycosides have been selected as key new product development projects in Shaanxi Province for 2024, indicating a breakthrough in natural product extraction technology [1] Group 2 - Chang'an Bank's financial support has been crucial for the growth trajectory of Huason Shengbang, with a fixed asset loan of 100 million yuan granted on September 20, 2024, specifically for the construction of a research center and procurement of high-end R&D equipment [1] - Chang'an Bank has developed a comprehensive service system covering nearly 40 products through its "Chang'an V+" microfinance brand, with a balance of 47.1 billion yuan in inclusive micro-enterprise loans and 170,000 loan accounts by the end of 2024 [1] - The case of Huason Shengbang reflects Chang'an Bank's deep logic in serving the private economy, having established a "three-special mechanism" to address the characteristics of sci-tech enterprises, providing not only funding but also value-added services such as industry analysis and policy connection [2]